{
	"l1liuv38Text": "<span style=\"color: rgba(76, 126, 133, 0);\">Anhedonia</span><span class=\"_ _13\"></span>Elderly<span class=\"_ _14\"></span>Asian<span class=\"_ _15\"> </span>Working popula<span class=\"_ _1\"></span>tion",
	"l1liuv39Text": "EEfRT<span class=\"_ _16\"> </span><span class=\"ff2 fc1 ws12\">MADRS/SDS<span class=\"_ _17\"></span><span class=\"ff6 fc0\">SHAPS/MADRS</span></span>",
	"l1liuv3aText": "Anhedonia",
	"l1liuv3bText": "Brintellix<span class=\"fse wsd v6\">®</span><span class=\"ws4\"> significantly impr<span class=\"_ _1\"></span>oved measures of <br><span class=\"ws13\">anhedonia<span class=\"fse wsd v6\">†</span></span><span class=\"v0\"> and functioning<span class=\"fse wsd v6\">‡</span> in MDD<span class=\"_ _1\"></span>,<span class=\"_ _1\"></span>  with a clear<br>dose r<span class=\"_ _1\"></span>esponse<span class=\"fse v6\">§1</span></span></span>",
	"l1liuv3tText": "Zoom",
	"Brintellix_NewAss_409499fc7": "<div style=\"color:#4d7f86; font-size:20px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; line-height:1.2\">Mean difference in change from baseline<br>in MADRS anhedonia subscale score<br>vs. placebo (FAS, MMRM)</div>",
	"Brintellix_NewAss_49edd8a1d": "<div style=\"color:#4d7f86; font-size:20px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; line-height:1.2\">Mean difference in change from<br>baseline in SDS total score<br>vs. placebo (FAS, MMRM)</div>",
	"Brintellix_NewAss_4e7307a5d": "<div style=\"text-align: center; color:#4d7f86; font-size:15px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; line-height:1.2\">Mean difference in change from<br>baseline vs. placebo</div>",
	"Brintellix_NewAss_477aeabfe": "<div style=\"text-align: center; color:#4d7f86; font-size:15px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; line-height:1.2\">Mean difference in change from<br>baseline vs. placebo</div>",
	"Brintellix_NewAss_4b78125b3": "<div style=\"text-align: center; color:#80878f; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold';\">**</div>",
	"Brintellix_NewAss_43228695a": "<div style=\"text-align: center; color:#80878f; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold';\">***</div>",
	"Brintellix_NewAss_4a861dfc0": "<div style=\"text-align: center; color:#80878f; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold';\">***</div>",
	"Brintellix_NewAss_453ebdfdc": "<div style=\"text-align: center; color:#80878f; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold';\">***</div>",
	"Brintellix_NewAss_446ab366a": "<div style=\"text-align: center; color:#80878f; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold';\">***</div>",
	"Brintellix_NewAss_4efd8e769": "<font style=\"color:#e88200; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:12px;\">Brintellix<sup style=\"font-size:50%;\">®</sup> 5 mg</font>",
	"Brintellix_NewAss_4e67fac6b": "<font style=\"color:#578f99; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:12px;\">Brintellix<sup style=\"font-size:50%;\">®</sup> 10 mg</font>",
	"Brintellix_NewAss_4fd1b9c20": "<font style=\"color:#cc66cc; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:12px;\">Brintellix<sup style=\"font-size:50%;\">®</sup> 15 mg</font>",
	"Brintellix_NewAss_484e7ffaa": "<font style=\"color:#5e6b73; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:12px;\">Brintellix<sup style=\"font-size:50%;\">®</sup> 20 mg</font>",
	"Brintellix_NewAss_49970bec4": "<div style=\"color:#646162; font-size:17px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-15px; margin-bottom:50px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:25px;\">•</b> In a post-hoc analysis of a 12-week, randomised, active-controlled trial, Brintellix<sup style=\"font-size:50%;\">®</sup> (10-20 mg/day)<br>demonstrated a superior effect on anhedonia and functioning vs. agomelatine (25-50 mg/day) as early<br>as week 4<sup style=\"font-size:50%;\">¶1</sup></div>",
	"Brintellix_NewAss_454df6748": "<div style=\"color:#5f6a72; font-size:11px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">\n**p&lt;0.01; ***p&lt;0.001 vs. placebo.<br>\n<sup style=\"font-size:50%;\">†</sup>As measured by MADRS 5-item anhedonia subscale, based on the following MADRS items: 1 (apparent sadness), 2 (reported sadness), 6<br>(concentration difficulties), 7 (lassitude), and 8 (inability to feel).<br>\n<sup style=\"font-size:50%;\">‡</sup>As measured by SDS.<br>\n<sup style=\"font-size:50%;\">§</sup>Pooled analysis of 11 short-term (6-8 weeks), double-blind, randomised, placebo-controlled studies of Brintellix<sup style=\"font-size:50%;\">®</sup> (fixed dose, 5–20 mg/day)<br>in patients with MDD (n=4988).<br>\n<sup style=\"font-size:50%;\">¶</sup>Statistically  significant differences for changes from baseline in MADRS anhedonia subscale score (-1.13, p=0.005 at week 4; -1.02, p=0.027<br>at week 12) and SDS total score (-2.50, p&lt;0.001 at week 4; -1.75, p=0.021 at week 12).<sup style=\"font-size:50%;\">1</sup><br>\n*Fictitious patient. FAS, full analysis set; MADRS, Montgomery–Åsberg depression rating scale; MDD, major depressive disorder; MMRM,<br>mixed-model repeated-measures analysis; SDS, Sheehan disability scale.\n</div>",
	"Brintellix_NewAss_498a02d32": "<span style=\"color: rgb(77, 127, 134); font-family: '2_TKMNLA+AvenirNextLTPro-Bold';\"><font style=\"font-size: 25px;\">References</font></span>",
	"Brintellix_NewAss_47bdec7a1": "<font style=\"font-size: 15px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi'; color: rgb(100, 94, 94);\"><b>1.</b></font>",
	"Brintellix_NewAss_4228d9c50": "<div style=\"margin-bottom:5px;\"><font style=\"font-size: 15px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);\">McIntyre RS et al. Neuropsychiatr Dis Treat 2021;17:575-585.</font></div>",
	"Brintellix_NewAss_4757653a2": "Text",
	"Brintellix_NewAss_4e4f51836": "Text",
	"Brintellix_NewAss_474eb6ec8": "Text",
	"Brintellix_NewAss_415856da4": "Text",
	"Brintellix_NewAss_435e5d7ac": "Text"
}
